Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 345,959 shares of the biopharmaceutical company's stock after purchasing an additional 29,563 shares during the period. ProShare Advisors LLC's holdings in Bristol-Myers Squibb were worth $19,567,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Transce3nd LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $34,000. Westend Capital Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $38,000. Finally, Tacita Capital Inc acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Up 2.1%

Bristol-Myers Squibb stock opened at $46.77 on Friday. The firm's 50-day moving average is $53.05 and its 200-day moving average is $55.97. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a market cap of $95.18 billion, a P/E ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the firm posted ($4.40) EPS. The company's revenue for the quarter was down 5.6% on a year-over-year basis. On average, equities analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were issued a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.30%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BMY. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Jefferies Financial Group dropped their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.